JPRN-UMIN000034387已完成未知
ong-term renoprotective effect of SGLT2 inhibitors - Renoprotection by SGLT2 inhibitors
ephrology Division, JA Toride Medical Center0 个研究点目标入组 60 人开始时间: 2018年11月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 15years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •nothing particular
研究者
相似试验
已完成
3 期
Evaluation Renoprotective Effect SGLT2 inhibitors on Prognosis of Transplant Kidney PatientsCondition 1: Diabetes mellitus type 2. Condition 2: Transplant Kidney.Type 2 diabetes mellitus with kidney complicationsKidney transplant statusE11.2Z94.0IRCT20220708055414N1Orchidpharmed30
招募中
2 期
Comparison of the renoprotective effects of SGLT2 inhibitor (Empagliflozin) in diabetic and non-diabetic kidney transplantation patientsIRCT20130812014333N168Kermanshah University of Medical Sciences28
进行中（未招募）
1 期
The RECEDE-CHF TrialType 2 diabetes and heart failureMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-003968-39-GBniversity of Dundee/NHS Tayside23
招募中
Unknown
The Renal Protective Effect Of SGLT2 Inhibitor Drug In Diabetics Patient Who Are Undergoing Per cutaneous Coronary Interventions.CTRI/2023/10/058896GSM Institute of Pharmaceutical Science
Unknown
4 期
Effect of SGLT2 inhibitor on Renal Function and Urinary [TIMP-2] x [IGFBP7] in Patients Hospitalized for Acute Heart Failure; A Randomized Controlled TrailAcute kidney injury and urinary [TIMP-2] x [IGFBP7] in patient hospitalized for acute heart failureAcute kidney injury, urinary [TIMP-2] x [IGFBP7], nephrocheck, acute heart failure, acute decompensated heart failure, SGLT2 inhibitor, renal function, biomarkerTCTR20221003002/A66